Benzinga - by Benzinga Insights, Benzinga Staff Writer.
A large exercise of company stock options by Jean Lori Robinson, Director at Centene (NYSE:CNC) was disclosed in a new SEC filing on February 15, as part of an insider exercise.
What Happened: Robinson, Director at Centene, made a strategic move by exercising stock options for 10,000 shares of CNC as detailed in a Form 4 filing on Thursday with the U.S. Securities and Exchange Commission. The transaction value amounted to $237,100.
Currently, Centene shares are trading up 0.08%, priced at $78.36 during Friday's morning. This values Robinson's 10,000 shares at $237,100.
Delving into Centene's Background Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 24 million medical members as of June 2023, mostly in Medicaid (67% of membership), the individual exchanges (14%), and Medicare Advantage (6%) plans. The company also serves traditional Medicare users with its Medicare Part D pharmaceutical program.
Financial Insights: Centene Revenue Growth: Centene's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 3.73%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Key Profitability Indicators:
- Gross Margin: The company faces challenges with a low gross margin of 9.28%, suggesting potential difficulties in cost control and profitability compared to its peers.
- Earnings per Share (EPS): Centene's EPS reflects a decline, falling below the industry average with a current EPS of 0.08.
Exploring Valuation Metrics Landscape:
- Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 15.82, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
- Price to Sales (P/S) Ratio: The current P/S ratio of 0.28 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
- EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): At 7.13, Centene's EV/EBITDA ratio reflects a below-par valuation compared to industry averages signalling undervaluation
Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.
Delving Into the Significance of Insider Transactions Insightful as they may be, insider transactions should be considered alongside a thorough examination of other investment criteria.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
A Closer Look at Important Transaction Codes Surveying the realm of stock transactions, investors often give prominence to those unfolding in the open market, systematically detailed in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
Check Out The Full List Of Centene's Insider Trades.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.